CNS Pharmaceuticals Inc., a Nevada-based corporation, has announced the entry into a placement agency agreement with A.G.P./Alliance Global Partners for a public offering. The offering includes 325,000 shares of the company's common stock and pre-funded warrants to purchase 3,627,570 shares of common stock, as well as Series F Warrants for an aggregate of 3,952,570 shares. The combined purchase price for each common stock share and accompanying warrant was set at $1.265, while the pre-funded warrant and accompanying warrant were priced at $1.264. The offering was made under a Registration Statement filed with the Securities and Exchange Commission, and the company has entered into a Securities Purchase Agreement with an institutional investor participating in the offering.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.